Literature DB >> 24572175

Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.

E Sally Ward1, Ramraj Velmurugan2, Raimund J Ober3.   

Abstract

The role of FcRn in regulating antibody levels and transport in the body is well documented. The use of fluorescence microscopy to investigate the subcellular trafficking behavior of FcRn and its IgG ligand has led to insight into the function of this receptor, including the identification of new intracellular pathways. The inhibition of FcRn using engineered antibodies that bind to this receptor with increased affinity through their Fc region can be exploited to treat antibody mediated autoimmunity. The efficacy of this approach in mouse models of arthritis and multiple sclerosis has been demonstrated. Finally, the cross-species difference between mouse and man for FcRn-IgG interactions needs to be considered when engineering antibodies for improved activities in FcRn-mediated functions.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody engineering; Antibody pharmacokinetics; Autoimmunity; FcRn; Immunoglobulin G; Live-imaging microscopy

Mesh:

Substances:

Year:  2014        PMID: 24572175      PMCID: PMC4058420          DOI: 10.1016/j.imlet.2014.02.008

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  62 in total

Review 1.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 2.  Pathology of demyelinating diseases.

Authors:  Bogdan F Gh Popescu; Claudia F Lucchinetti
Journal:  Annu Rev Pathol       Date:  2012       Impact factor: 23.472

3.  Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

Authors:  Dilip K Challa; Uta Bussmeyer; Tarique Khan; Héctor P Montoyo; Pankaj Bansal; Raimund J Ober; E Sally Ward
Journal:  MAbs       Date:  2013-06-19       Impact factor: 5.857

Review 4.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

5.  Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway.

Authors:  Zhuo Gan; Sripad Ram; Raimund J Ober; E Sally Ward
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

Review 6.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

7.  Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.

Authors:  Dipesh A Patel; Alberto Puig-Canto; Dilip Kumar Challa; Héctor Perez Montoyo; Raimund J Ober; E Sally Ward
Journal:  J Immunol       Date:  2011-06-20       Impact factor: 5.422

8.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

9.  The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL/6-immunized mice.

Authors:  Pankaj Bansal; Tarique Khan; Uta Bussmeyer; Dilip K Challa; Rafal Swiercz; Ramraj Velmurugan; Raimund J Ober; E Sally Ward
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

10.  Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery.

Authors:  Zhuo Gan; Sripad Ram; Carlos Vaccaro; Raimund J Ober; E Sally Ward
Journal:  Traffic       Date:  2009-01-24       Impact factor: 6.215

View more
  6 in total

Review 1.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Authors:  Jonathan T Sockolosky; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2015-02-19       Impact factor: 15.470

2.  Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris.

Authors:  Yumay Chen; Alex Chernyavsky; Robert J Webber; Sergei A Grando; Ping H Wang
Journal:  J Biol Chem       Date:  2015-08-10       Impact factor: 5.157

3.  Cell surface dynamics and cellular distribution of endogenous FcRn.

Authors:  Lena D'Hooghe; Andrew D Chalmers; Sam Heywood; Paul Whitley
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

Review 4.  The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the "Super Compensation Hypothesis".

Authors:  Animesh A Sinha; Thomas Sajda
Journal:  Front Med (Lausanne)       Date:  2018-08-14

5.  Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.

Authors:  Bryan Smith; Andrea Kiessling; Rocio Lledo-Garcia; Kate L Dixon; Louis Christodoulou; Matthew C Catley; Paul Atherfold; Lena E D'Hooghe; Helene Finney; Kevin Greenslade; Hanna Hailu; Lara Kevorkian; Daniel Lightwood; Christoph Meier; Rebecca Munro; Omar Qureshi; Kaushik Sarkar; Sophie P Shaw; Roohi Tewari; Alison Turner; Kerry Tyson; Shauna West; Stevan Shaw; Frank R Brennan
Journal:  MAbs       Date:  2018-09-12       Impact factor: 5.857

6.  Abl family tyrosine kinases govern IgG extravasation in the skin in a murine pemphigus model.

Authors:  Sachiko Ono; Gyohei Egawa; Takashi Nomura; Akihiko Kitoh; Teruki Dainichi; Atsushi Otsuka; Saeko Nakajima; Masayuki Amagai; Fumi Matsumoto; Mami Yamamoto; Yoshiaki Kubota; Toshiyuki Takai; Tetsuya Honda; Kenji Kabashima
Journal:  Nat Commun       Date:  2019-09-30       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.